Sun Pharma Announces Pre-Clinical Data on GL0034, an Experimental NCE to Treat Type 2 Diabetes and Obesity

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced an update on the pre-clinical molecule, for which a disclosure was made in the Q1FY20 results press release. The experimental New Chemical Entity (NCE), GL0034 is a long-acting GLP-1R (Glucagon-Like Peptide-1 Receptor) agonist. Such agonists are used to treat patients with type 2 diabetes, including short-acting, intermediate-acting, and long-acting therapies.

The pre-clinical data for GL0034 was recently presented at the American Diabetes Association (ADA) Virtual 80th Scientific Sessions. GL0034 has been developed internally by Sun Pharma's High Impact Innovations - Sustainable Health Solutions (HISHS) Discovery Team.

Pre-clinical performance of GL0034 was assessed in a highly relevant type 2 diabetes db/db mouse model. The NCE demonstrated significant outcomes on various diabetic parameters evaluated, viz. glucose reduction, decrease in HbA1c (an important marker for clinical efficacy), augmented insulin secretion, lowering of glucagon level and a marked and meaningful reduction in triglyceride levels. All these outcomes with GL0034 were found to be higher or significant to the currently marketed once a week GLP-1R agonists compared in the study.

Yet another important feature in diabetes treatment is weight management. GL0034 induced a larger body weight reduction, 1.9x and 3.8x times higher than the two different standard once a week GLP-1R agonist drugs compared in the study, with similar food consumption.

Dilip Shanghvi, Managing Director, Sun Pharma said, "We are excited by the robust pre-clinical data for GL0034 and believe that it has significant potential. We look forward to validating this data in human clinical trials."

Sun Pharma is planning to initiate Phase-1 clinical trials for GL0034 by Q3FY21.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.500.4 as compared to the previous close of Rs. 493.1. The total number of shares traded during the day was 364693 in over 6935 trades.

The stock hit an intraday high of Rs. 502.9 and intraday low of 489.8. The net turnover during the day was Rs. 181719663.

Source : Equity Bulls

Keywords